Trial no.:
|
PACTR202407850473997 |
Date of Approval:
|
16/07/2024 |
Trial Status:
|
Registered in accordance with WHO and ICMJE standards |
|
TRIAL DESCRIPTION |
Public title
|
Perioperative Dexamethasone Compared with Placebo as an Adjunct Pain Relief on Women Undergoing Caesarean Section at Federal Medical Centre, Owo: Randomized Controlled Trial |
Official scientific title |
Perioperative Dexamethasone Compared with Placebo as an Adjunct Pain Relief on Women Undergoing Caesarean Section at Federal Medical Centre, Owo: Randomized Controlled Trial |
Brief summary describing the background
and objectives of the trial
|
Caesarean section is associated with tissue damage which results in release of chemical mediators that stimulate inflammatory response by nociceptors. This leads to postoperative pain which is the major complaint after Caesarean section. Opioids are majorly used for postoperative analgesia. However, its use is associated with some unwanted side effects which limit its availability and appropriate use. Dexamethasone is a glucocorticoid which has an anti-inflammatory role and may reduce the need for opioids consumption or the dose required for postoperative pain with additional benefit on postoperative nausea and vomiting.
Objectives of the study are:
i. To assess for postoperative pain scores after Caesarean section in FMC, Owo.
ii. To determine the time for first request for postoperative analgesia in women who had Caesarean section in FMC, Owo.
iii. To assess opioid (pentazocine) sparing effect in women who had Caesarean section in FMC, Owo.
iv. To determine the effect of Dexamethasone on postoperative nausea and vomiting in women who had Caesarean section in FMC, Owo.
v. To determine the effect of Dexamethasone on postoperative haemodynamic status in women who had Caesarean section in FMC, Owo.
vi. To assess for patient’s satisfaction to this intervention.
|
Type of trial |
RCT |
Acronym (If the trial has an acronym then please provide) |
|
Disease(s) or condition(s) being studied |
Obstetrics and Gynecology |
Sub-Disease(s) or condition(s) being studied |
None |
Purpose of the trial |
Treatment: Drugs |
Anticipated trial start date |
05/07/2024 |
Actual trial start date |
05/07/2024 |
Anticipated date of last follow up |
06/09/2024 |
Actual Last follow-up date |
|
Anticipated target sample size (number of participants) |
146 |
Actual target sample size (number of participants) |
|
Recruitment status |
Recruiting |
Publication URL |
|
|